Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
26
pubmed:dateCreated
2007-6-5
pubmed:abstractText
Plasmid-based IL-12 has been demonstrated to successfully enhance the immunogenicity of DNA vaccines, thus enabling a reduction of the amount of DNA required for immunization. IL-15 is thought to affect the maintenance and enhance effector function of CD8(+) memory T cells. Since the ability to elicit a long-term memory response is a desirable attribute of a prophylactic vaccine, we sought to evaluate the ability of these plasmid-based cytokines to serve as vaccine adjuvants in rhesus macaques. Macaques were immunized with plasmid DNA encoding SIVgag in combination with plasmid IL-12, IL-15, or a combination of IL-12 and IL-15. The plasmid-based cytokines were monitored for their ability to augment SIVgag-specific cellular and humoral immune responses and to alter the clinical outcome following pathogenic SHIV(89.6P) challenge. Macaques receiving SIVgag pDNA in combination with plasmid IL-12 alone, or in combination with plasmid IL-12 and IL-15, demonstrated significantly elevated cell-mediated and humoral immune responses resulting in an improved clinical outcome following virus challenge compared to macaques receiving SIVgag pDNA alone. Macaques receiving SIVgag pDNA in combination with plasmid IL-15 alone demonstrated minor increases in cell-mediated and humoral immune responses, however, the clinical outcome following virus challenge was not improved. These results have important implications for the continued development of plasmid DNA vaccines for the prevention of HIV-1 infection.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
21
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4967-82
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17335943-Animals, pubmed-meshheading:17335943-Antibodies, Viral, pubmed-meshheading:17335943-Antibody Formation, pubmed-meshheading:17335943-CD4 Lymphocyte Count, pubmed-meshheading:17335943-CD4-Positive T-Lymphocytes, pubmed-meshheading:17335943-CD8-Positive T-Lymphocytes, pubmed-meshheading:17335943-Disease Progression, pubmed-meshheading:17335943-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:17335943-Gene Products, gag, pubmed-meshheading:17335943-Immunity, Cellular, pubmed-meshheading:17335943-Interferon-gamma, pubmed-meshheading:17335943-Interleukin-12, pubmed-meshheading:17335943-Interleukin-15, pubmed-meshheading:17335943-Macaca mulatta, pubmed-meshheading:17335943-Male, pubmed-meshheading:17335943-Neutralization Tests, pubmed-meshheading:17335943-Plasmids, pubmed-meshheading:17335943-SAIDS Vaccines, pubmed-meshheading:17335943-Simian Acquired Immunodeficiency Syndrome, pubmed-meshheading:17335943-Vaccines, DNA
pubmed:year
2007
pubmed:articleTitle
Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.
pubmed:affiliation
Wyeth Vaccines Discovery, 401 N. Middletown Road, Pearl River, NY 10965, USA. chongs@wyeth.com
pubmed:publicationType
Journal Article, Comparative Study, Research Support, N.I.H., Extramural